Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage of Bodycote at 'buy'

(Sharecast News) - Berenberg initiated coverage of Bodycote on Monday with a 'buy' rating and "conservatively set" 800p price target. "Bodycote's financial framework is targeting 20% operating margins in the medium term, with low-investment requirements and self-help opportunities, gearing towards industrial cyclical recovery and strong cash generation, which we believe is undervalued at current levels compared to the industrial engineering sector," the bank said.

It said Bodycote is an early-cycle operationally-geared industrial recovery play.

"While industrial indicators are weak and visibility is low, along with other factors we note here, the exposure to a recovery is very high compared to our broader industrials coverage," Berenberg said.

"Furthermore, on a 12-month view, with comps easing and the likelihood of industrial markets stabilising, we believe that there is the potential for earnings to accelerate, although we also note that our EPS forecasts for 2025 are slightly ahead of consensus forecasts."

In addition, it said Bodycote has one of the highest exposures in the bank's coverage to attractive aerospace and defence markets, which should underpin group growth in the medium term.

Berenberg noted that Bodycote has historically maintained a strong balance sheet, with low investment requirements and resulting strong cash generation.

"This provides scope for further M&A and improved returns to shareholders, in addition to the current £60m share buyback," it said.

Berenberg also pointed to an attractive valuation, with Bodycote trading on 12.7x FY 2024E price-to-earnings and 10.1x FY 2024 EV/EBIT.

"These are substantial discounts to Bodycote's own historical levels as well as the sector relative history of 15% and 16% on a P/E basis respectively," it said.

"The stock has rarely traded this low in comparison to its sector, thus suggesting to us that the stock is pricing-in a lot of cyclical headwinds and not much credit for self-help initiatives."

Share this article

Related Sharecast Articles

Waitrose partners with Just Eat in new convenience partnership
(Sharecast News) - Waitrose announced on Thursday it is partnering with Just Eat on a multi-year deal to bring rapid deliveries to customers across 229 UK locations in the coming weeks.
Great Portland reaffirms ERV guidance after strong quarter
(Sharecast News) - London real estate developer Great Portland Estates reaffirmed annual rental value guidance after a strong three months to the end of September, adding that an improving economy, falling interest rates and scarcity of supply would drive growth.
Auction Technology Group lowers full-year guidance as CFO steps down
(Sharecast News) - Auction Technology Group said it expects full-year revenues to be slightly shy of earlier guidance as it announced the resignation of its chief financial officer.
GSK to pay $2.2bn to settle Zantac lawsuits
(Sharecast News) - GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.